DK1414438T3 - Antineoplastiske kombinationer - Google Patents
Antineoplastiske kombinationerInfo
- Publication number
- DK1414438T3 DK1414438T3 DK02768432T DK02768432T DK1414438T3 DK 1414438 T3 DK1414438 T3 DK 1414438T3 DK 02768432 T DK02768432 T DK 02768432T DK 02768432 T DK02768432 T DK 02768432T DK 1414438 T3 DK1414438 T3 DK 1414438T3
- Authority
- DK
- Denmark
- Prior art keywords
- antineoplastic combinations
- antineoplastic
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31064601P | 2001-08-07 | 2001-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1414438T3 true DK1414438T3 (da) | 2006-03-27 |
Family
ID=23203475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02768432T DK1414438T3 (da) | 2001-08-07 | 2002-08-06 | Antineoplastiske kombinationer |
Country Status (27)
Country | Link |
---|---|
US (4) | US6617333B2 (xx) |
EP (2) | EP1671943A1 (xx) |
JP (2) | JP2005505549A (xx) |
KR (1) | KR20040029406A (xx) |
CN (3) | CN101279983A (xx) |
AR (2) | AR036250A1 (xx) |
AT (1) | ATE314069T1 (xx) |
AU (2) | AU2002330994B2 (xx) |
BR (1) | BR0211769A (xx) |
CA (1) | CA2455126A1 (xx) |
CY (1) | CY1104983T1 (xx) |
DE (1) | DE60208385T2 (xx) |
DK (1) | DK1414438T3 (xx) |
EA (2) | EA006226B1 (xx) |
ES (1) | ES2252512T3 (xx) |
HK (1) | HK1061204A1 (xx) |
HU (1) | HUP0401089A3 (xx) |
IL (2) | IL159859A0 (xx) |
MX (1) | MXPA04001118A (xx) |
NO (2) | NO325503B1 (xx) |
NZ (3) | NZ542272A (xx) |
PL (1) | PL368303A1 (xx) |
SG (1) | SG170612A1 (xx) |
TW (2) | TWI300351B (xx) |
UA (1) | UA77200C2 (xx) |
WO (1) | WO2003020266A1 (xx) |
ZA (1) | ZA200401801B (xx) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US20060199811A1 (en) * | 1997-07-31 | 2006-09-07 | Pfirrmann Rolf W | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
SK288546B6 (sk) | 2001-02-19 | 2018-03-05 | Novartis Ag | 40-O-(2-hydroxyetyl)rapamycín v kombinácii s exemestánom alebo letrozolom na použitie pri liečení nádoru prsníka |
TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
EP1389209B1 (en) | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
AU2003243226A1 (en) * | 2002-05-15 | 2003-12-02 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
US20040122048A1 (en) * | 2002-10-11 | 2004-06-24 | Wyeth Holdings Corporation | Stabilized pharmaceutical composition containing basic excipients |
CL2004000016A1 (es) | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
ES2395082T3 (es) | 2003-01-27 | 2013-02-08 | Endocyte, Inc. | Conjugado de folato-vinblastina como medicamento |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
ES2279407T3 (es) * | 2003-04-22 | 2007-08-16 | Wyeth | Combinaciones antineoplasicas. |
RU2006106267A (ru) * | 2003-08-01 | 2006-07-27 | Уайт Холдингз Корпорейшн (Us) | Применение комбинации ингибитора киназы рецептора эпидермального фактора роста и цитотоксических средств для лечения и ингибирования рака |
AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
PE20050928A1 (es) * | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
UA84903C2 (ru) * | 2004-01-08 | 2008-12-10 | Уайет | Фармацевтическая композиция для перорального использования ссі-779, полученная прямым прессованием |
UA85698C2 (ru) * | 2004-01-16 | 2009-02-25 | Уайет | Хинолиновые промежуточные соединения для синтеза ингибиторов рецепторной тирозинкиназы и способ их получения |
US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
MX2007005153A (es) * | 2004-10-28 | 2007-06-26 | Wyeth Corp | Uso de un inhibidor del mtor en el tratamiento de leiomioma del utero. |
US10603314B2 (en) | 2005-02-03 | 2020-03-31 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
NZ577283A (en) | 2005-03-07 | 2010-11-26 | Robarts Res Inst | Use of a Myxoma virus that does not express functional M135R |
CN101175757B (zh) * | 2005-03-16 | 2012-11-14 | 恩多塞特公司 | 蝶酸及其缀合物的合成和纯化 |
TW200716557A (en) * | 2005-05-25 | 2007-05-01 | Wyeth Corp | Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof |
JP2008542267A (ja) * | 2005-05-25 | 2008-11-27 | ワイス | 3−シアノ−キノリンと、それにより製造される中間体とを調製する方法 |
CA2608589A1 (en) * | 2005-05-25 | 2006-11-30 | Wyeth | Methods of synthesizing 6-alkylaminoquinoline derivatives |
CN101252931A (zh) * | 2005-06-24 | 2008-08-27 | 惠氏公司 | 用于治疗癌症的4-苯胺基-3-喹啉甲腈 |
PL1902029T5 (pl) * | 2005-07-01 | 2022-08-29 | Wyeth Llc | Krystaliczne postacie 4-[(2,4-dichloro-5-metoksyfenylo)amino]-6-metoksy-7-[3(-4-metylo-1-piperazynylo)propoksy]-3-chinolino-karbonitrylu i sposoby ich wytwarzania |
BRPI0615354A2 (pt) * | 2005-08-19 | 2011-05-17 | Endocyte Inc | conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso |
EP1948240A2 (en) * | 2005-08-19 | 2008-07-30 | Endocyte, Inc. | Ligand conjugates of vinca alkaloids, analogs and derivatives |
JP2009514870A (ja) * | 2005-11-04 | 2009-04-09 | ワイス | mTORインヒビター、ハーセプチン、および/またはHKI−272の抗悪性腫瘍性組み合わせ |
AU2016259316B2 (en) * | 2005-11-04 | 2018-09-06 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272 |
AU2013204788B2 (en) * | 2005-11-04 | 2016-12-08 | Wyeth Llc | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
WO2007057457A2 (en) | 2005-11-21 | 2007-05-24 | Novartis Ag | Neuroendocrine tumor treatment using mtor inhibitors |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
WO2008101231A2 (en) * | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
WO2008121467A2 (en) * | 2007-02-28 | 2008-10-09 | Dana-Farber Cancer Institute, Inc. | Combination therapy for treating cancer |
CN101678124A (zh) * | 2007-03-14 | 2010-03-24 | 恩多塞特公司 | 结合配体连接的微管溶素递药缀合物 |
TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
JP5690589B2 (ja) * | 2007-06-25 | 2015-03-25 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 親水性スペーサーリンカーを含有する結合体 |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
US20090076060A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched temsirolimus |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
WO2009055562A1 (en) | 2007-10-25 | 2009-04-30 | Endocyte, Inc. | Tubulysins and processes for preparing |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
KR20110010787A (ko) | 2008-06-17 | 2011-02-07 | 와이어쓰 엘엘씨 | Hki-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
EP3175853B1 (en) | 2008-08-04 | 2023-11-01 | Wyeth LLC | Antineoplastic combinations of neratinib and capecitabine |
JP2012510489A (ja) * | 2008-12-02 | 2012-05-10 | バイオコンパティブルズ ユーケー リミテッド | 膵がんの治療 |
JP5992325B2 (ja) | 2009-04-06 | 2016-09-14 | ワイス・エルエルシー | 乳癌のための、ネラチニブを活用する治療計画 |
ES2622881T3 (es) | 2010-09-29 | 2017-07-07 | Intervet International B.V. | Compuestos de N-heteroarilo |
WO2012041872A1 (en) | 2010-09-29 | 2012-04-05 | Intervet International B.V. | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
JP2015536323A (ja) | 2012-10-16 | 2015-12-21 | エンドサイト・インコーポレイテッドEndocyte, Inc. | 非天然アミノ酸を含む薬物送達結合体および使用方法 |
WO2014182635A1 (en) | 2013-05-08 | 2014-11-13 | Baldwin Megan E | Biomarkers for age-related macular degeneration (amd) |
US9242965B2 (en) * | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
KR20180094923A (ko) | 2015-12-24 | 2018-08-24 | 교와 핫꼬 기린 가부시키가이샤 | α, β 불포화 아미드 화합물 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU415255A1 (ru) * | 1972-03-20 | 1974-02-15 | Т. А. Асонова, А. Я. Берлин, А. Б. Зезин, Е. Ф. Разводовский | СПОСОБ ПОЛУЧЕНИЯ р-БЕТАИ1ЮВВПТВci)iia aiisn^pii |
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US4194050A (en) | 1976-04-30 | 1980-03-18 | Sumitomo Chemical Company, Limited | Process for producing an enamide |
US4195021A (en) | 1977-10-26 | 1980-03-25 | Eli Lilly And Company | 1,3-Disubstituted 2-azetidinone antibitotics |
US4193983A (en) | 1978-05-16 | 1980-03-18 | Syva Company | Labeled liposome particle compositions and immunoassays therewith |
US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
BE897134A (fr) | 1983-06-24 | 1983-12-27 | Solvay | Dienes polysubstitues |
US4478959A (en) | 1983-09-29 | 1984-10-23 | Air Products And Chemicals, Inc. | Amino and amido divalent metal carboxylates useful as catalysts for polyurethane formulations |
DE3347659A1 (de) | 1983-12-31 | 1985-07-11 | Bayer Ag, 5090 Leverkusen | Neue lackloesungen auf der basis von hydantoingruppen enthaltenden polymeren |
US4664825A (en) | 1984-10-25 | 1987-05-12 | The Lubrizol Corporation | Sulfurized compositions and lubricants containing them |
US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
AU634871B2 (en) | 1990-03-20 | 1993-03-04 | Banyu Pharmaceutical Co., Ltd. | Substituted amine derivatives having anti-hyperlipemia activity |
US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
ATE135583T1 (de) | 1991-06-18 | 1996-04-15 | American Home Prod | Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen |
ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
CN1069492A (zh) * | 1991-08-21 | 1993-03-03 | 山之内制药株式会社 | 4-酰胺基咪唑衍生物 |
US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
US5352783A (en) | 1993-06-09 | 1994-10-04 | Merck & Co., Inc. | Microbial transformation product having immunosuppressive activity |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
US5547948A (en) | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
JP2002541200A (ja) * | 1999-04-14 | 2002-12-03 | デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド | 癌の処置のための方法および組成物 |
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
WO2002013802A2 (en) * | 2000-08-11 | 2002-02-21 | Wyeth | Method of treating estrogen receptor positive carcinoma |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
CL2004000016A1 (es) | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
-
2002
- 2002-06-08 UA UA2004031662A patent/UA77200C2/uk unknown
- 2002-08-02 TW TW091117467A patent/TWI300351B/zh active
- 2002-08-02 TW TW095110188A patent/TWI305527B/zh active
- 2002-08-06 WO PCT/US2002/024841 patent/WO2003020266A1/en active Application Filing
- 2002-08-06 US US10/212,889 patent/US6617333B2/en not_active Ceased
- 2002-08-06 JP JP2003524573A patent/JP2005505549A/ja not_active Withdrawn
- 2002-08-06 SG SG200600623-3A patent/SG170612A1/en unknown
- 2002-08-06 MX MXPA04001118A patent/MXPA04001118A/es active IP Right Grant
- 2002-08-06 AR ARP020102977A patent/AR036250A1/es unknown
- 2002-08-06 NZ NZ542272A patent/NZ542272A/en unknown
- 2002-08-06 IL IL15985902A patent/IL159859A0/xx unknown
- 2002-08-06 NZ NZ530847A patent/NZ530847A/en unknown
- 2002-08-06 HU HU0401089A patent/HUP0401089A3/hu unknown
- 2002-08-06 KR KR10-2004-7001883A patent/KR20040029406A/ko not_active Application Discontinuation
- 2002-08-06 EA EA200400284A patent/EA006226B1/ru not_active IP Right Cessation
- 2002-08-06 ES ES02768432T patent/ES2252512T3/es not_active Expired - Lifetime
- 2002-08-06 EP EP05019642A patent/EP1671943A1/en not_active Withdrawn
- 2002-08-06 DE DE60208385T patent/DE60208385T2/de not_active Expired - Fee Related
- 2002-08-06 PL PL02368303A patent/PL368303A1/xx unknown
- 2002-08-06 NZ NZ560845A patent/NZ560845A/en unknown
- 2002-08-06 CN CNA2008100810681A patent/CN101279983A/zh active Pending
- 2002-08-06 BR BR0211769-0A patent/BR0211769A/pt not_active IP Right Cessation
- 2002-08-06 EP EP02768432A patent/EP1414438B1/en not_active Expired - Lifetime
- 2002-08-06 AU AU2002330994A patent/AU2002330994B2/en not_active Ceased
- 2002-08-06 CA CA002455126A patent/CA2455126A1/en not_active Abandoned
- 2002-08-06 CN CNB028153480A patent/CN1326523C/zh not_active Expired - Fee Related
- 2002-08-06 AT AT02768432T patent/ATE314069T1/de not_active IP Right Cessation
- 2002-08-06 CN CNB2006100025108A patent/CN100415753C/zh not_active Expired - Fee Related
- 2002-08-06 EA EA200501251A patent/EA200501251A1/ru not_active IP Right Cessation
- 2002-08-06 DK DK02768432T patent/DK1414438T3/da active
-
2004
- 2004-01-14 IL IL159859A patent/IL159859A/en not_active IP Right Cessation
- 2004-02-06 NO NO20040558A patent/NO325503B1/no not_active IP Right Cessation
- 2004-03-04 ZA ZA200401801A patent/ZA200401801B/en unknown
- 2004-06-15 HK HK04104313A patent/HK1061204A1/xx not_active IP Right Cessation
-
2005
- 2005-09-08 US US11/222,485 patent/USRE40418E1/en not_active Expired - Lifetime
- 2005-11-25 AR ARP050104937A patent/AR051778A2/es unknown
-
2006
- 2006-02-22 CY CY20061100255T patent/CY1104983T1/el unknown
- 2006-10-24 AU AU2006233165A patent/AU2006233165B2/en not_active Ceased
- 2006-12-22 US US11/645,327 patent/USRE41084E1/en not_active Expired - Fee Related
-
2007
- 2007-07-20 NO NO20073801A patent/NO20073801L/no not_active Application Discontinuation
- 2007-10-26 US US11/978,093 patent/USRE41253E1/en not_active Expired - Lifetime
-
2010
- 2010-01-22 JP JP2010011652A patent/JP2010155845A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1414438T3 (da) | Antineoplastiske kombinationer | |
IS7291A (is) | Merkt kirni | |
DE50204184D1 (de) | Espressobrüheinrichtung | |
ATE524462T1 (de) | C5-modifizierte indazolylpyrrolotriazine | |
DE50208022D1 (de) | Wischblatt | |
DE50206021D1 (de) | Schlauchklemme | |
DE50103741D1 (de) | Welle-Nabe-Verbindung | |
DE50204386D1 (de) | Kreuztransducer | |
DE50209238D1 (de) | Kugelgelenk | |
DE60205841D1 (de) | Perfluoroelastomere | |
DE1319930T1 (de) | Coriolismassendurchflussmesser | |
DE50211604D1 (de) | Chlag | |
DE50209410D1 (de) | Kugelgelenk | |
NO20035317D0 (no) | Antineoplastiske kombinasjoner | |
DE50208372D1 (de) | Schrankaufhängevorrichtung | |
DE50204551D1 (de) | Kugelgelenk | |
DE50204794D1 (de) | Kugelgelenk | |
DE50203412D1 (de) | Schwenkkolbenverdränger | |
DE50203984D1 (de) | Kugelgelenk | |
DE50211290D1 (de) | Handzange | |
DE50208029D1 (de) | Kugelgelenk | |
ATE355059T1 (de) | Isoxazolopyridinone | |
DE50201862D1 (de) | Messwandler | |
DE50203093D1 (de) | Losradlager | |
DE50209293D1 (de) | Amidpolymermasse |